Identification of therapeutic targets for inflammation in sickle cell disease (SCD) among Indian patients using gene expression data analysis

Sickle cell disease (SCD) is life-threatening hemoglobinopathy prevalent in India, Sub-Saharan Africa and Middle East. Inflammation plays a pivotal role in disease process and involves intricate interaction among leukocytes, platelets, sickle erythrocytes and vascular endothelium. Available disease modifying therapies are hydroxyl-urea and blood transfusion. Therefore, it is of interest to develop improved pharmacological agents for SCD. We report up-regulated genes in steady state and vaso-occlusive crisis using analysis of gene expression data obtained by microarray experiment for SCD as potential targets. The association of these targets with inflammation in pathway analysis is also documented.

• Publication year

  2018

• Venue

  Bioinformation

• Publication date

  2018-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.6026/97320630014408PMID 30262980PMCID 6143353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inflammation in sickle cell disease

  2018cited by this paper
• Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease.

  2015cited by this paper
• Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia

  2015cited by this paper
• Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy

  2015cited by this paper
• Toxicity of Hydroxyurea in Rats and Dogs

  2015cited by this paper
• Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.

  2015cited by this paper
• Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia

  2015cited by this paper
• A century after discovery of sickle cell disease: keeping hope alive!

  2014cited by this paper
• Inflammatory mediators of endothelial injury in sickle cell disease.

  2014cited by this paper
• [Sickle cell pathophysiology].

  2014cited by this paper
• Versican and the control of inflammation.

  2014cited by this paper
• Galectin-3: its role in asthma and potential as an anti-inflammatory target

  2013cited by this paper
• Relevance of alloimmunization in haemolytic transfusion reaction in sickle cell disease.

  2012cited by this paper
• Inflammation Amplification by Versican: The First Mediator

  2012cited by this paper
• Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

  2012cited by this paper
• Galectin 3 as a novel therapeutic target in rheumatoid arthritis: comment on the article by Forsman et al.

  2011cited by this paper
• Leukotriene pathway in sickle cell disease: a potential target for directed therapy

  2009cited by this paper
• Galectin‐3 regulates T‐cell functions

  2009cited by this paper
• Asthma and sickle cell disease: two distinct diseases or part of the same process?

  2009cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Global epidemiology of haemoglobin disorders and derived service indicators.

  2008cited by this paper
• Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients.

  2008cited by this paper
• Therapy preference and decision‐making among patients with severe sickle cell anemia and their families &

  2007cited by this paper
• Versican G3 Domain Promotes Blood Coagulation through Suppressing the Activity of Tissue Factor Pathway Inhibitor-1*

  2006cited by this paper
• DNA MICROARRAY TECHNOLOGY FOR TARGET IDENTIFICATION AND VALIDATION

  2006cited by this paper
• Inhibitors of NF-kappaB signaling: 785 and counting.

  2006cited by this paper
• Pediatr Blood Cancer

  2004cited by this paper
• Identification of a human NF-kappaB-activating protein, TAB3.

  2004cited by this paper
• The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy

  2004cited by this paper
• CD89: the human myeloid IgA Fc receptor.

  2001cited by this paper
• The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy.

  2001cited by this paper
• Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion.

  2000cited by this paper
• Sickle cell anemia as an inflammatory disease.

  2000cited by this paper
• Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

  1998cited by this paper
• Treatment of myeloproliferative syndrome with hydroxyurea

  1996cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Role of ions and extracellular protein in leukocyte motility and membrane ruffling.

  1978cited by this paper
• Thermodynamic studies of polymerization of deoxygenated sickle cell hemoglobin.

  1976cited by this paper

• Sickle cell health awareness, perspectives and experiences (SHAPE) survey: perspectives on sickle cell disease (SCD) from healthcare providers in India, Malaysia, and Thailand

  2025cites this paper
• Can we use biomarkers to identify those at risk of acute pain from sickle cell disease?

  2024cites this paper